Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clindamycin + gentamicin is a combination of two antibiotics used primarily for the treatment of serious infections, notably pelvic inflammatory disease (PID). Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, providing strong activity against anaerobic bacteria and some Gram-positive organisms. Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, disrupting protein synthesis and exhibiting bactericidal activity mainly against aerobic Gram-negative bacteria. The combination leverages their complementary spectra to cover both anaerobic and aerobic pathogens commonly implicated in severe gynecological or intra-abdominal infections[1][3][5]. This regimen is recommended by clinical guidelines for PID and has demonstrated efficacy in clinical studies[1][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clindamycin + gentamicin.